A Hazard of Being a Researcher
Similar Posts
Generic Doesn‘t Mean Affordable
ByadminGeneric meds are supposed to be relatively cheap; multiple companies can make the same molecule, leading to price-lowering competition. But that’s not always what happens in the US market. Look at the prices of these generics, in the US vs Canada: We need to take regulatory or legislative steps to reduce the price of generic…
Power of Analogy
ByadminFrom time to time in this blog, I take a moment to celebrate fine writing. Here is an example I came across in an article in Smithsonian magazine from May 2014. The author, Corey Powell , was trying to explain how astronomers use gravitational “tug” to indirectly reveal the existence of planets. In other words, they can’t…
The Ulysses Strategy
Byadmin“The Ulysses Strategy” – The New Yorker
Health Insurance Trends in One Picture
ByadminHere is data from the CDC, on the percent of Americans without health insurance. It shows that Obamacare, for all its strengths and weaknesses, is definitely addressing one major problem in the US:
Specialty Drugs at Especially High Prices
ByadminThere have been many wonderful new medications in the past decade or so, drugs that finally bring hope for many people with serious illnesses like rheumatoid arthritis, multiple sclerosis and even some advanced cancers. But these drugs often come at a high price. Here is a snapshot of drug spending in 2014, courtesy of the…
Price Transparency Thoughts from a Thought Leader (And Former Student)
ByadminHere is a great piece on my former student, Jessica Harris, who now works in health care price transparency at Aetna. She visited my class this summer, and here are some of the things she taught them: The evolution of transparency in the industry: “2013 and 2014 have been really important years for transparency and…